Pharmacology/Pharmaceutical Industry
RCT | In older patients undergoing total intravenous anesthesia, Etomidate is noninferior to Propofol regarding the risk of major postoperative complications.
11 Aug, 2022 | 12:18h | UTC
Commentary on Twitter
General anesthesia with etomidate does not increase postoperative morbidity, as indicated by the rate of major in-hospital post-op complications, in elderly patients undergoing abdominal surgery, as compared with propofol. https://t.co/vjPvle3DQj pic.twitter.com/2k6eSLupbH
— JAMA Surgery (@JAMASurgery) August 10, 2022
RCT | Tobramycin inhalation solution is effective in adults with bronchiectasis with pseudomonas aeruginosa infection.
11 Aug, 2022 | 12:15h | UTCCommentary: Tobramycin Tames Infection in Bronchiectasis – Medscape (free registration required)
RCT | Effect of intranasal Dexmedetomidine or Midazolam for premedication on the occurrence of respiratory adverse events in children undergoing tonsillectomy and adenoidectomy.
11 Aug, 2022 | 12:08h | UTCCommentaries:
Dexmedetomidine Cuts Perioperative Respiratory AEs in Tonsillectomy – HealthDay
Commentary on Twitter
Children often required sedatives before surgery due to anxiety and crying. In this RCT, intranasal midazolam increased the incidence of perioperative respiratory adverse events (PRAEs), while intranasal dexmedetomidine reduced PRAEs. #OrigInvestigation https://t.co/5AAILuzstM pic.twitter.com/WejpGkAGGs
— JAMA Network Open (@JAMANetworkOpen) August 9, 2022
Cohort Study | Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes.
11 Aug, 2022 | 11:54h | UTC
Commentary on Twitter
Study showed men with #T2DM on GnRH for prostate cancer had a 53% higher risk of an increase in CVD risk score than those not on GnRH, suggesting the need to control cardiovascular disease risk factors in men with T2DM receiving GnRH. #OrigInvestigation https://t.co/3cJ10PpQGN
— JAMA Network Open (@JAMANetworkOpen) August 8, 2022
RCT | Effect of a comprehensive telehealth intervention vs. telemonitoring and care coordination in patients with persistently poor type 2 diabetes control.
9 Aug, 2022 | 12:44h | UTCEffect of a Comprehensive Telehealth Intervention vs Telemonitoring and Care Coordination in Patients With Persistently Poor Type 2 Diabetes Control: A Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)
Commentary on Twitter
A comprehensive telehealth intervention improved HbA1c in persistently poorly-controlled type 2 diabetes compared to a simpler telehealth intervention; the comprehensive telehealth approach may warrant implementation in systems with appropriate resources. https://t.co/qXnuclyipQ
— JAMA Internal Medicine (@JAMAInternalMed) July 29, 2022
RCT | Efficacy and safety of intravenous acetaminophen (2 g/day) for reducing opioid consumption in Chinese adults after elective orthopedic surgery.
9 Aug, 2022 | 12:39h | UTC
Inhaled antibiotics in critical care: state of the art and future perspectives.
9 Aug, 2022 | 12:30h | UTC
RCT | Antiseptic skin agents to prevent surgical site infection after incisional surgery.
8 Aug, 2022 | 11:54h | UTCAntiseptic Skin Agents to Prevent Surgical Site Infection After Incisional Surgery: A Randomized, Three-armed Combined Non-inferiority and Superiority Clinical Trial (NEWSkin Prep Study) – Annals of Surgery (link to abstract – $ for full-text)
Related:
Two randomized trials found monoclonal antibodies are no better than placebo for Parkinson’s Disease.
8 Aug, 2022 | 11:53h | UTCStudy 1: Trial of Cinpanemab in Early Parkinson’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Study 2: Trial of Prasinezumab in Early-Stage Parkinson’s Diseas – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Monoclonal Antibodies No Better Than Placebo for Early Parkinson Disease – HealthDay
Cochrane Collection | Achieving sustainable healthcare through deprescribing of unnecessary medications: making sense of the evidence.
8 Aug, 2022 | 11:50h | UTC
Antimicrobial dosing recommendations in pediatric continuous renal replacement therapy: a critical appraisal of current evidence.
5 Aug, 2022 | 13:58h | UTC
Case-Control Study | Outpatient oral macrolide use is associated with increased risk of sensorineural hearing loss in children, adolescents, and young adults.
4 Aug, 2022 | 14:29h | UTCAssociation of Outpatient Oral Macrolide Use With Sensorineural Hearing Loss in Children, Adolescents, and Young Adults – JAMA Otolaryngology-Head & Neck Surgery (link to abstract – $ for full-text)
Commentary: Kids’ Hearing Loss Associated With Common Antibiotics — Children and teens with sensorineural hearing loss more often macrolide users – MedPage Today (free registration required)
Cohort Study | The risk of opioid overdose is increased with concomitant use of oxycodone and selective serotonin reuptake inhibitors that are inhibitors of oxycodone metabolism.
4 Aug, 2022 | 14:27h | UTCCommentary from the author: Taking certain opioids while on commonly prescribed antidepressants may increase the risk of overdose – The Conversation
Commentary on Twitter
This cohort study found that concomitant use of oxycodone with potent CYP2D6-inhibiting serotonin reuptake inhibitors (SSRIs, eg. fluoxetine or paroxetine) is associated with an increased risk of overdose. https://t.co/Eol89RHWAu
— JAMA Network Open (@JAMANetworkOpen) February 24, 2022
M-A | Efficacy of Doxycycline for mild-to-moderate community-acquired pneumonia in adults.
4 Aug, 2022 | 14:17h | UTCEfficacy of Doxycycline for Mild-to-moderate Community-acquired Pneumonia in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials – Clinical Infectious Diseases (link to abstract – $ for full-text)
Commentary on Twitter
🆕⚡⚡Systematic Review and Meta-analysis of Randomized Controlled Trials @CIDJournal
Efficacy of Doxycycline for Mild-to-moderate CAP in Adults
The efficacy of doxycycline was comparable to macrolides or fluoroquinolones in mild-moderate CAP #IDTwitter https://t.co/L7UBBUc4Dm— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) July 29, 2022
RCT | Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis.
4 Aug, 2022 | 13:28h | UTCComparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial – The Lancet Neurology (link to abstract – $ for full-text)
Commentary: Less Frequent Dosing With MS Drug Safe With No Loss of Efficacy – Medscape (free registration required)
M-A | Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials.
3 Aug, 2022 | 14:31h | UTC
RECOVERY Trial | Baricitinib in patients admitted to hospital with COVID-19.
3 Aug, 2022 | 14:34h | UTCInvited Commentary: Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality – The Lancet
Related:
WHO recommends two new drugs to treat COVID-19 – World Health Organization
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine
Commentary on Twitter
New @TheLancet
The largest trial of baricitinib, a JAK-inhibitor drug repurposed via #AI data mining, reduced Covid mortality and the overall reduction consistent with 8 previous RCTs (~20%)https://t.co/5fHDBBvm3Q pic.twitter.com/GDFzcU26H6— Eric Topol (@EricTopol) July 29, 2022
Under a Creative Commons Attribution (CC BY 4.0) license
Evidence Synthesis | Deprescribing medicines in older people living with multimorbidity and polypharmacy.
3 Aug, 2022 | 14:20h | UTCRelated:
Antihypertensive Deprescribing in Older Adults: a Practical Guide – Current Hypertension Reports
Deprescribing in Palliative Cancer Care – Life
Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review – Kidney360
Polypharmacy Management in Older Patients – Mayo Clinic Proceedings
Eliminating Medication Overload: A National Action Plan – Lown Institute
Common ED Medication Errors: Polypharmacy – emDocs
Current and future perspectives on the management of polypharmacy – BMC Family Practice
Polypharmacy—an Upward Trend with Unpredictable Effects – Deutsches Ärzteblatt international
Clinical Consequences of Polypharmacy in Elderly – Expert Opinion on Drug Safety
Guideline | Androgen deprivation therapy: adverse events and management strategies.
3 Aug, 2022 | 14:15h | UTC
RCT | Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction.
3 Aug, 2022 | 14:06h | UTC
Commentary on Twitter
No one wants to add meds just so you can add more meds. BUT, adding patiromer in select patients with HFrEF so you can optimize GDMT sure is compelling… 🤔 https://t.co/79gSEwon4y
— ATRIUM Cardiology (@ATRIUMRx) July 29, 2022
RCT | Safety and efficacy of Tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan.
2 Aug, 2022 | 12:05h | UTCSafety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
See also (note: the dulaglutide dosage used in this trial was probably suboptimal): Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Related:
Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Online—Safety and efficacy of #tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 #diabetes in #Japan (#SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial https://t.co/r4v4QUsl5q #T2D pic.twitter.com/k6ihWy2vem
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 31, 2022
Review | Management of heart failure in patients with chronic kidney disease.
1 Aug, 2022 | 11:59h | UTCManagement of Heart Failure in Patients with Chronic Kidney Disease – European Cardiology Review
M-A | Cardiovascular and venous thromboembolic risk with Janus Kinase inhibitors in immune-mediated inflammatory diseases.
1 Aug, 2022 | 11:52h | UTC
A large observational study suggests long-acting injectable antipsychotics are associated with better outcomes than oral antipsychotics in people with schizophrenia.
29 Jul, 2022 | 12:25h | UTCInvited Commentary: Improving Outcomes in Schizophrenia—A Case for Initiation of Long-Acting Antipsychotics in Early-Phase Illness – JAMA Network Open
Related:
Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia – The Journal of Clinical Psychiatry (link to abstract – $ for full-text)
Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis – The Lancet (link to abstract – $ for full-text)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link to abstract – $ for full-text)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
This case series of people with schizophrenia found long-acting injectable antipsychotics were associated with less disease relapse and hospitalization vs oral antipsychotics, w/o an increased risk of adverse events. @Esther_CSMPRHKU @HKUPharm @hkumed https://t.co/ZiPkV4lSk0
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
Perspective | Climbing melatonin use for insomnia raises safety concerns.
28 Jul, 2022 | 13:24h | UTCClimbing Melatonin Use for Insomnia Raises Safety Concerns – JAMA (free for a limited period)